Qiagen's Singapore play

Qiagen N.V. announced plans last week to establish a Singaporean joint venture that will combine its expertise in the field of assay development with BioOne Capital Pte. Ltd.'s inside access to local research institutions and hospitals. The new company, Dx Assays Pte. Ltd., will develop assays for infectious diseases that incorporate pathogens specific to Asia.

According to Jean-Paul Viola, the research tool company's executive director of business development for Asia-Pacific, "right now Asia is the fastest growing market for Qiagen, so it makes strategic sense to continue to strengthen our presence in the area." While the company will maintain its other assay development facilities in the U.S., Europe and China, Singapore offered a number of unique opportunities, he said...